Reva Medical (ASX:RVA) said this week that it’s expanding a trial of its Fantom bioabsorbable drug-eluting stent to Europe, a few months after launching the study in Brazil.
The 1st implantation in Europe for the Fantom II clinical trial took place in Denmark, the San Diego-based company said. Fantom is delivered through either the femoral artery in the groin or the radial artery in the wrist. Like traditional metal stents, it’s designed to expand and prop up an artery in order to clear it of blocked plaque. Unlike those stents, however, Fantom is designed to dissolve and disappear in the body over time.
Chairman & CEO Bob Stockman said in prepared remarks that the company expects to present initial results from the trial at EuroPCR in Paris next month. The trial launched in Brazil last December.
Reva has said it’s gunning to complete required testing and submit its CE Mark application in 2016.
The company pulled in a $25 million debt-and-options round in November 2014.